Used in the treatment of autoimmune disorders such as rheumatoid arthritis and psoriasis by selectively inhibiting Janus kinase 1 (JAK1), which plays a key role in inflammatory signaling pathways. It modulates immune response and reduces symptoms of chronic inflammation. Also under investigation for use in certain cancers due to its role in cytokine signaling regulation. Shows high selectivity, leading to fewer off-target effects compared to broader kinase inhibitors. Administered orally, with good bioavailability and favorable pharmacokinetic profile in clinical settings.